Investors & media
Financial data
Find the latest press releases, financial information, and performance updates.
Transforming rare disease care
We are a specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.
Newsroom
2025.06.18
JCR Pharmaceuticals announces launch of mucopolysaccharidosis (MPS) type II disease awareness film featured in The Next Frontier series
2025.07.15
JCR Pharmaceuticals and Acumen Pharmaceuticals announce collaboration to develop therapy for Alzheimer’s disease, enabled by J-Brain Cargo® technology platform
2025.07.08
JCR pharmaceuticals enters license agreement with Alexion for proprietary JUST-AAV capsids to be used in the development of genomic medicines
2025.07.02
JCR Pharmaceuticals announces the achievement of enrollment in the JR-141 global phase III clinical trial
2025.06.25
Notice of resolutions passed at the 50th ordinary general meeting of shareholders
2025.06.25
Matters concerning controlling shareholders (affiliated companies)
Performance data
JCR Pharmaceuticals (4552.T)
Tokyo Currency in JPY
603.00
+2.00
(+0.33%)
Last updated 07/15/2025 at TSE market close
Quarterly results
Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.
Contact us
Investors & media